Brief: Prometheus Biosciences Completes Enrollment Of Artemis-UC Cohort 1 Phase 2 Study In Ulcerative Colitis
18/07/2022 14:11
July 18 (Reuters) - Prometheus Biosciences Inc RXDX.O :
* PROMETHEUS BIOSCIENCES COMPLETES ENROLLMENT OF THE
ARTEMIS-UC
COHORT 1 PHASE 2 STUDY IN ULCERATIVE COLITIS
* PROMETHEUS BIOSCIENCES INC - ENROLLMENT INITIATED IN
COHORT 2 OF
CDX+ PATIENTS TO EVALUATE COMPANY'S COMPANION DIAGNOSTIC
* PROMETHEUS BIOSCIENCES INC - BOTH APOLLO-CD AND ARTEMIS-UC
TOPLINE RESULTS ON TRACK FOR 4Q 2022
Source text for Eikon: ID:nGNX3Z9XJP
Further company coverage: RXDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prometheus Biosciences
See all newsBrief: Prometheus Biosciences - Completed Merger Of Splash Merger Sub, Unit Of Merck & Co
Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
William Blair sees FTC suit on Amgen-Horizon deal weighing on biotech M&A sentiment
FTC scrutiny to block Amgen-Horizon deal drags down Seagen, Prometheus
Brief: Prometheus Biosciences Reports First Quarter 2023 Financial Results